Vasopressor SAT Study

An Assessment of Vasoactive Medication Dose in Mechanically Ventilated Patients Undergoing Daily Sedation Awakening Trial (SAT)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03182335

Enrollment

800

Registered

2017-06-09

Start date

2014-04-28

Completion date

2026-11-01

Last updated

2026-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Critical Illness, Delirium, Low Blood Pressure

Brief summary

To assess the impact of daily awakening from sedation on the amount of vasoactive medication required in the ICU. The hypothesis of this proposal is that the amount of vasoactive drug required to maintain an adequate mean arterial blood pressure will be reduced during a daily awakening from sedation.

Detailed description

This observational study will compare mean arterial pressure and vasoactive drug dose recorded at two time points: 1. prior to awakening from sedation 2. during the awakening from sedation trial The vasoactive infusion will be titrated to a mean arterial pressure as determined by the medical team prior to study enrollment. Each enrolled patient will have measurements taken only on the first day of enrollment. Enrolled subjects will also have a delirium assessment using the CAM-ICU tool before the awakening from sedation trial and during the awakening from sedation trial.

Interventions

OTHERsedation awakening trial

vital signs and delirium assessment (CAM-ICU) at baseline then following routine sedation awakening trial. Patient will thus serve as their own control for these interventions

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* requiring Mechanical ventilation through an endotracheal tube with infusion of sedative or analgesic agent for comfort * requiring vasoactive drug via central venous catheter for the treatment of shock

Exclusion criteria

* patients receiving Dexmedetomidine as sedative

Design outcomes

Primary

Measure	Time frame	Description
change in vasoactive drug dose	baseline thru study completion on average < 4 hrs	mcg/kg/min baseline dose and nadir dose

Secondary

Measure	Time frame	Description
change in mean arterial blood pressure	baseline thru study completion on average <4 hrs	mm Hg
change in prevalence of ICU delirium	baseline thru study completion on average <4hrs	CAM ICU score

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORJohn Kress, MD

University of Chicago

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 14, 2026